07:46 AM EDT, 09/03/2025 (MT Newswires) -- ProMIS Neurosciences ( PMN ) said Wednesday it received the recommendation of the Data and Safety Monitoring Board to proceed with the third and final dose escalation of its phase 1b trial of PMN310 lead product candidate for the treatment of Alzheimer's disease.

The recommendation was based on the review of the available safety data through the trial's cohort 2, with no cases of amyloid-related imaging abnormalities observed to date, the company said.

ProMIS said the enrollment of patients in cohort 3 is now ongoing, with the trial on track to deliver six-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026.

The company's shares were up more than 11% in recent premarket activity on Wednesday.

Price: 0.60, Change: +0.06, Percent Change: +11.41